A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

Summary

This is a Phase 1/2 study to investigate the safety and efficacy of the CAR-T therapy, ONCT-808, in patients with relapsed/refractory (R/R) aggressive B cell malignancies.

Timeline

Start

2023-05-09

Primary completion

2024-09-12

Completion

2024-09-12

Outcome

Outcome not reported

Stopped: “Based on the available clinical data and capital requirements for continued development, the Company has decided to terminate this study.”

Drugs

Indications